Literature DB >> 29169114

Evaluation of antiparkinson activity of PTUPB by measuring dopamine and its metabolites in Drosophila melanogaster: LC-MS/MS method development.

Navya Lakkappa1, Praveen T Krishnamurthy2, Karthik Yamjala3, Sung Hee Hwang4, Bruce D Hammock4, B Babu3.   

Abstract

Soluble epoxide hydrolase (sEH) inhibition is reported to elevate endogenous epoxyeicosatrienoic acids (EET's), which are known to play an important role in neuroprotection by inhibiting oxidative stress and neuroinflammation. In the present study, PTUPB, a dual inhibitor of sEH and COX-2, has been tested for its antiparkinson activity against rotenone (ROT) induced neurodegeneration in Drosophila model of Parkinson's disease (PD). To determine the efficacy and brain bioavailability of PTUPB a simple, rapid and sensitive LC-MS/MS method was developed and validated for the estimation of PTUPB (Method-I), dopamine (DA) and its metabolites (Method-II) in fly head. Mass spectrometric acquisitions of analytes signals were performed in positive and negative electron spray ionization MRM mode by monitoring the daughter ions. The isocratic elution using formic acid (0.1% v/v) and acetonitrile (20:80v/v) (for method I), and acetic acid (0.1% v/v) and methanol (for method II) on Jones C18 was carried out to achieve the separation. The results of brain PTUPB, DA and its metabolites estimation shows a dose dependent increase in PTUPB concentration and a dose dependent prevention of ROT induced changes in DA and its metabolites levels (p<0.05), indicating a significant neuroprotection activity of PTUPB. In the present study, we have successfully developed and validated LC-MS/MS methods to identify and quantify PTUPB, DA and its metabolites using a UFLC-ESI-QqQ mass spectrometer for the screening of neuroprotective agents in Drosophila Melanogaster.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drosophila model; Dual sEH and COX-2 inhibitor; LC–MS/MS method; PTUPB; Parkinson disease

Mesh:

Substances:

Year:  2017        PMID: 29169114      PMCID: PMC5843369          DOI: 10.1016/j.jpba.2017.11.043

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  20 in total

1.  Prophylactic treatment with Bacopa monnieri leaf powder mitigates paraquat-induced oxidative perturbations and lethality in Drosophila melanogaster.

Authors:  Ravikumar Hosamani
Journal:  Indian J Biochem Biophys       Date:  2010-04       Impact factor: 1.918

2.  Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.

Authors:  Guodong Zhang; Dipak Panigrahy; Sung Hee Hwang; Jun Yang; Lisa M Mahakian; Hiromi I Wettersten; Jun-Yan Liu; Yanru Wang; Elizabeth S Ingham; Sarah Tam; Mark W Kieran; Robert H Weiss; Katherine W Ferrara; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

Review 3.  Drosophila as a model to study mitochondrial dysfunction in Parkinson's disease.

Authors:  Ming Guo
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

4.  A rapid radioimmunoassay for serum testosterone.

Authors:  P E Sheldon; C J Coppenger
Journal:  Steroids       Date:  1977-08       Impact factor: 2.668

5.  An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes.

Authors:  B Samuelsson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster.

Authors:  Hélène Coulom; Serge Birman
Journal:  J Neurosci       Date:  2004-12-01       Impact factor: 6.167

Review 7.  Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases.

Authors:  Luisa Minghetti
Journal:  J Neuropathol Exp Neurol       Date:  2004-09       Impact factor: 3.685

8.  Capillary electrophoresis-mass spectrometry-based detection of drugs and neurotransmitters in Drosophila brain.

Authors:  Nhu T N Phan; Jörg Hanrieder; E Carina Berglund; Andrew G Ewing
Journal:  Anal Chem       Date:  2013-08-19       Impact factor: 6.986

9.  Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disorders.

Authors:  Navya Lakkappa; Praveen T Krishnamurthy; Bruce D Hammock; D Velmurugan; M M Srinivas Bharath
Journal:  Med Hypotheses       Date:  2016-06-05       Impact factor: 1.538

10.  Neuroprotective efficacy of Bacopa monnieri against rotenone induced oxidative stress and neurotoxicity in Drosophila melanogaster.

Authors:  Ravikumar Hosamani
Journal:  Neurotoxicology       Date:  2009-09-08       Impact factor: 4.294

View more
  8 in total

Review 1.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

Review 2.  Soluble Epoxide Hydrolase as a Therapeutic Target for Neuropsychiatric Disorders.

Authors:  Jiajing Shan; Kenji Hashimoto
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

3.  Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression.

Authors:  Anna Fishbein; Weicang Wang; Haixia Yang; Jun Yang; Victoria M Hallisey; Jianjun Deng; Sanne M L Verheul; Sung Hee Hwang; Allison Gartung; Yuxin Wang; Diane R Bielenberg; Sui Huang; Mark W Kieran; Bruce D Hammock; Dipak Panigrahy
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-14       Impact factor: 11.205

Review 4.  Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity.

Authors:  Kerstin Hiesinger; Karen M Wagner; Bruce D Hammock; Ewgenij Proschak; Sung Hee Hwang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-12-26       Impact factor: 3.072

Review 5.  The Role of Lipids in Parkinson's Disease.

Authors:  Helena Xicoy; Bé Wieringa; Gerard J M Martens
Journal:  Cells       Date:  2019-01-07       Impact factor: 6.600

Review 6.  Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.

Authors:  Mercè Pallàs; Santiago Vázquez; Coral Sanfeliu; Carles Galdeano; Christian Griñán-Ferré
Journal:  Biomolecules       Date:  2020-05-01

Review 7.  Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances.

Authors:  Yun Sheng; Hanyu Yang; Tong Wu; Liang Zhu; Li Liu; Xiaodong Liu
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

Review 8.  Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.

Authors:  Cheng-Peng Sun; Xin-Yue Zhang; Christophe Morisseau; Sung Hee Hwang; Zhan-Jun Zhang; Bruce D Hammock; Xiao-Chi Ma
Journal:  J Med Chem       Date:  2020-12-28       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.